<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68791">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01865240</url>
  </required_header>
  <id_info>
    <org_study_id>008/12</org_study_id>
    <secondary_id>NHMRC</secondary_id>
    <nct_id>NCT01865240</nct_id>
  </id_info>
  <brief_title>Renal Denervation for Resistant Hypertension</brief_title>
  <acronym>RDNP-2012-01</acronym>
  <official_title>Renal Denervation for Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker IDI Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker IDI Heart and Diabetes Institute</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study investigating the effectiveness of renal denervation in lowering blood
      pressure in people whose blood pressure is not adequately controlled despite treatment with
      3 or more blood pressure lowering drugs. The study is designed to compare the effects of
      renal denervation to a usual care group receiving additional blood pressure lowering drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies have shown that the renal denervation procedure is safe and effective in
      reducing blood pressure in patients with resistant hypertension.   A total of 100
      participants with uncontrolled blood pressure, treated with three or more blood pressure
      lowering medications will be recruited into the study. Patients will be assigned to one (1)
      of two (2) groups with the aim of attaining blood pressure control. Participants in group 1
      will be assigned to renal denervation, participants in group 2 will receive additional
      antihypertensive medication according to current guidelines and best practice in an attempt
      to reach blood pressure targets.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>blood pressure control</measure>
    <time_frame>6 months post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>percentage of patients to achieve BP target  (BP &lt;140/90mmHg, or &lt;130/80mmHg in diabetic patients) at 6 months post procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of drugs required to reach blood pressure target</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of drugs required to reach blood pressure target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to achieve blood pressure target</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>time to achieve blood pressure target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of sympathetic nerve activity</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in muscle sympathetic nerve activity (MSNA), renal and whole body NE spillover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Structure and Function</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Left Ventricular mass index, ejection fraction, diastolic filling as assessed by echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Quality of Life as assessed by relevant questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Urine Biochemistry</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Plasma renin activity, aldosterone, eGFR, UACR, inflammatory markers, 24hour urinary creatinine clearance, sodium, fasting glucose, fasting insulin, c-peptide, HOMA index, lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of arterial stiffness</measure>
    <time_frame>baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in markers of arterial stiffness incduing AI and PWV</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal Denervation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants randomised to undergo the renal denervation procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <description>Renal Denervation Catheter</description>
    <arm_group_label>Renal Denervation Group</arm_group_label>
    <other_name>Symplicity Renal Denervation Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  systolic BP ≥140mmHg or ≥130mmHg for patients with diabetes

          -  concurrent treatment with ≥3 anti-hypertensive drugs

        Exclusion Criteria:

          -  renal artery anatomy ineligible for treatment

          -  eGFR &lt;15mL/min/1.73m2 (using MDRD calculation)

          -  female participants of childbearing potential must have negative pregnancy test prior
             to treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Schlaich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker IDI Heart &amp; Diabetes Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus P Schlaich, MD</last_name>
    <phone>+61 3 8532 1502</phone>
    <email>markus.schlaich@bakeridi.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petra Marusic, B.App.Sci</last_name>
    <phone>+61 3 8532 1734</phone>
    <email>petra.marusic@bakeridi.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baker IDI Heart &amp; Diabetes Inst</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus P Schlaich, MD</last_name>
      <phone>+61 3 8532 1502</phone>
      <email>markus.schlaich@bakeridi.edu.au</email>
    </contact>
    <investigator>
      <last_name>Markus P Schlaich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>May 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal denervation</keyword>
  <keyword>blood pressure</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>target organ damage</keyword>
  <keyword>sympathetic activity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
